BioAtla Inc Dossier - Source-backed chat

BioAtla Inc

BCABNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.85

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.26Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.1M

Enterprise Value −$5M

Shares Outstanding 1.7M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BioAtla is a clinical-stage biopharmaceutical company that has transitioned into a formal strategic review process to explore options such as asset sales, licensing, or a corporate merger. Following a severe cash crunch, the company implemented a 70% workforce reduction in March 2026 and a 50-for-1 reverse stock split in April 2026 to maintain Nasdaq compliance. While its Conditionally Active Biologics (CAB) platform holds scientific merit, the company's extremely constrained liquidity ($2.0M in cash as of March 31, 2026) and going-concern warning make it a highly speculative situation. A 'Hold' is recommended as the stock's near-term direction will be entirely dictated by the outcome of its asset monetization and strategic review efforts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5025%

The strategic review process fails to yield a viable transaction, and the company is forced to wind down operations or liquidate, resulting in minimal to no recovery for common shareholders.

Base CaseCentral scenario

$5.5060%

The company successfully monetizes one or more of its clinical assets (such as ozuriftamab vedotin or mecbotamab vedotin) or secures a strategic merger, providing a modest premium over the current distressed market capitalization.

Bull CaseUpside scenario

$10.5015%

The company successfully partners or out-licenses its Phase 3-ready asset ozuriftamab vedotin (Oz-V) or other clinical assets, securing significant upfront non-dilutive funding and validating its Conditionally Active Biologic (CAB) platform, leading to a substantial re-rating of the stock.

Scenarios reflect our research view at the research date.

Key Investment Merits

Proprietary Conditionally Active Biologics (CAB) platform designed to target the acidic tumor microenvironment, potentially reducing systemic toxicity.
Short-term non-dilutive cash injection of $6.5 million secured via the May 2026 Context Therapeutics license amendment.
Substantial cost reductions achieved through a 70% workforce down-sizing, extending the immediate operational runway during the strategic review.

Key Investment Risks

Severe liquidity constraints with only $2.0 million in cash and cash equivalents as of March 31, 2026, triggering substantial doubt about the company's ability to continue as a going concern.
High execution risk surrounding the ongoing formal strategic review process, with no guarantee that any transaction will be finalized.
Complete dependence on external partners or buyers to fund or advance clinical-stage assets, as internal development has been effectively paused.

Thesis Invalidation Triggers

Termination of the strategic review process without a transaction.
Failure to receive the remaining $2.0 million payment from Context Therapeutics by August 1, 2026.
Nasdaq delisting proceedings if the company fails to maintain compliance post-reverse split.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.